PL90318B1 - - Google Patents

Download PDF

Info

Publication number
PL90318B1
PL90318B1 PL1973160769A PL16076973A PL90318B1 PL 90318 B1 PL90318 B1 PL 90318B1 PL 1973160769 A PL1973160769 A PL 1973160769A PL 16076973 A PL16076973 A PL 16076973A PL 90318 B1 PL90318 B1 PL 90318B1
Authority
PL
Poland
Prior art keywords
peptide
fatty acid
corticotropin
suspended
salt
Prior art date
Application number
PL1973160769A
Other languages
English (en)
Polish (pl)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CH229972A external-priority patent/CH574247A5/de
Application filed filed Critical
Publication of PL90318B1 publication Critical patent/PL90318B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL1973160769A 1972-02-17 1973-02-15 PL90318B1 (OSRAM)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH229972A CH574247A5 (en) 1972-02-17 1972-02-17 Oily, injectable peptide/aluminium alkanoate compsns - - with prolonged duration of activity
CH1782972 1972-12-07

Publications (1)

Publication Number Publication Date
PL90318B1 true PL90318B1 (OSRAM) 1977-01-31

Family

ID=25690055

Family Applications (1)

Application Number Title Priority Date Filing Date
PL1973160769A PL90318B1 (OSRAM) 1972-02-17 1973-02-15

Country Status (18)

Country Link
US (1) US3869549A (OSRAM)
JP (1) JPS4892516A (OSRAM)
AR (1) AR197116A1 (OSRAM)
AT (1) AT335615B (OSRAM)
AU (1) AU472655B2 (OSRAM)
BE (1) BE795516A (OSRAM)
CS (1) CS172967B2 (OSRAM)
DD (1) DD102584A5 (OSRAM)
DE (1) DE2306075A1 (OSRAM)
DK (1) DK134098B (OSRAM)
ES (1) ES411655A1 (OSRAM)
FR (1) FR2181734B1 (OSRAM)
GB (1) GB1418408A (OSRAM)
IE (1) IE37151B1 (OSRAM)
IL (1) IL41416A (OSRAM)
NL (1) NL7300953A (OSRAM)
PL (1) PL90318B1 (OSRAM)
SE (1) SE7600435L (OSRAM)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2254043C2 (de) * 1972-11-04 1985-01-24 Hoechst Ag, 6230 Frankfurt LH-Releasing Hormon zur nasalen Applikation
DE2254061A1 (de) * 1972-11-04 1974-05-16 Hoechst Ag Lh-releasing hormon zur nasalen applikation
JPS528375B2 (OSRAM) * 1973-07-02 1977-03-09
GB1575343A (en) * 1977-05-10 1980-09-17 Ici Ltd Method for preparing liposome compositions containing biologically active compounds
JPS55118415A (en) * 1979-02-28 1980-09-11 Pii Papahadojiyopo Dometoriosu Method of encapsulating biologically active substance in lipoid cell
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4933179A (en) * 1983-08-22 1990-06-12 Syntex (U.S.A.) Inc. Feline leukemia virus antigen vaccines
US4770874A (en) * 1983-08-22 1988-09-13 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
ES8702440A1 (es) * 1984-10-04 1986-12-16 Monsanto Co Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa.
US5474980A (en) * 1984-10-04 1995-12-12 Monsanto Company Prolonged release of biologically active somatotropins
US5086041A (en) * 1984-10-04 1992-02-04 Monsanto Company Methods of using prolonged release somatotropin compositions
US5411951A (en) * 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
DE3502099A1 (de) * 1985-01-23 1986-08-07 Dieter Prof. Dr. Dr. 5883 Kierspe Aderhold Therapeutisches, peptid- und/oder aminosaeurehaltiges mittel
US4650854A (en) * 1985-06-06 1987-03-17 Usv Pharmaceutical Corporation Amide analogs of calcitonin
US4804742A (en) * 1985-06-06 1989-02-14 Rorer Pharmaceutical Corporation Amide analogs of calcitonin
US4775659A (en) * 1985-08-19 1988-10-04 Eli Lilly And Company Injectable semi-solid formulations
ZA866218B (en) * 1985-08-23 1988-03-30 Lilly Co Eli Injectable sustained release formulation
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5179079A (en) * 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
US5635161A (en) * 1995-06-07 1997-06-03 Abbott Laboratories Aerosol drug formulations containing vegetable oils
KR19990071255A (ko) 1998-02-28 1999-09-15 성재갑 소마토트로핀과 비타민의 합제 조성물
US7258869B1 (en) * 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US8241670B2 (en) * 2004-04-15 2012-08-14 Chiasma Inc. Compositions capable of facilitating penetration across a biological barrier
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
GB0511269D0 (en) * 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
NZ572003A (en) 2006-05-30 2010-07-30 Intarcia Therapeutics Inc Two-piece, internal-channel osmotic delivery system flow modulator with spiral fluid channel
DK2049081T3 (da) 2006-08-09 2013-02-25 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelarrangementer
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
ES2717154T3 (es) 2007-06-22 2019-06-19 Univ Texas Formación de partículas de péptido o proteína submicrométricas estables mediante congelación de película fina
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
HRP20170929T1 (hr) 2008-09-17 2017-09-22 Chiasma Inc. Farmaceutski pripravci i odgovarajući postupci za isporuku
JP5711138B2 (ja) 2008-11-16 2015-04-30 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 高濃度の低粘度懸濁液
CA2775676C (en) 2009-09-28 2016-08-16 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2015158823A1 (de) 2014-04-16 2015-10-22 Veyx-Pharma Gmbh Veterinärpharmazeutische zusammensetzung und deren verwendung
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2016126830A1 (en) 2015-02-03 2016-08-11 Chiasma Inc. Method of treating diseases
CN107920884B (zh) 2015-06-03 2021-08-27 因塔西亚制药公司 植入物放置和移除系统
CL2016000217A1 (es) * 2016-01-27 2016-07-01 Farmacologia En Aquacultura Veterinaria Fav S A Nueva composición veterinaria inyectable para la sincronización del desove en peces
EP3458084B1 (en) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
US10835580B2 (en) 2017-01-03 2020-11-17 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE950676C (de) * 1948-01-06 1956-10-11 Bristol Lab Inc Verfahren zur Herstellung eines injizierbaren Arzneimittels
DE920148C (de) * 1951-03-31 1954-11-15 Nyegaard & Co As Verfahren zur Herstellung von Adrenocorticotrophin-Praeparaten mit verlaengerter Wirkungsdauer
US2944940A (en) * 1956-01-16 1960-07-12 Armour & Co Adrenocorticotrophin and zinc composition
US2945783A (en) * 1957-06-20 1960-07-19 Reheis Company Inc Aluminum protein antacid and process of making

Also Published As

Publication number Publication date
CS172967B2 (OSRAM) 1977-01-28
IE37151B1 (en) 1977-05-11
FR2181734B1 (OSRAM) 1975-10-10
AT335615B (de) 1977-03-25
SE7600435L (sv) 1976-01-16
JPS4892516A (OSRAM) 1973-11-30
FR2181734A1 (OSRAM) 1973-12-07
GB1418408A (en) 1975-12-17
DD102584A5 (OSRAM) 1973-12-20
AU5218973A (en) 1974-08-15
ES411655A1 (es) 1976-09-01
IL41416A (en) 1976-03-31
US3869549A (en) 1975-03-04
AR197116A1 (es) 1974-03-15
DK134098B (da) 1976-09-13
IL41416A0 (en) 1973-03-30
BE795516A (fr) 1973-08-16
DE2306075A1 (de) 1973-08-23
DK134098C (OSRAM) 1977-02-21
AU472655B2 (en) 1976-06-03
NL7300953A (OSRAM) 1973-08-21
IE37151L (en) 1973-08-17
ATA140873A (de) 1976-07-15

Similar Documents

Publication Publication Date Title
PL90318B1 (OSRAM)
RU2201248C2 (ru) Стабильный водный пептидный препарат, способ его получения и способ лечения гормонзависимого заболевания у субъекта
DE69738300T2 (de) Pharmazeutische zusammensetzungen mit verzoegerter freisetzung, die wasserunloesliche komplexverbindungen enthalten
AU2003235401B2 (en) Medicinal compositions containing ghrelin
US4476116A (en) Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
DE69432224T2 (de) Aerosole als darreichungsform mit cfc-freiem treibmittel
RU2203085C2 (ru) Стабильный неводный препарат пептидного соединения, способ его получения и способ лечения гормон-зависимого заболевания у субъекта
FI95202C (fi) Menetelmä diabetes mellituksen hoitoon tarkoitetun farmaseuttisen valmisteen valmistamiseksi
EP1404357B1 (en) Gonadotropin releasing hormone antagonist in gel-forming concentrations
EP3102184B1 (en) Stable peptide formulations and methods for preparation
JPH10508294A (ja) 薬用組成物からのペプチドの持続的放出
HU218281B (en) Process for producing cetrorelix acetate liophylizate and pharmaceutical composition containing them
JP2025004006A (ja) テベレリクス－ｔｆａ組成物
KR100633280B1 (ko) 약제학적 활성 펩티드의 서방형 투여 형태 및 이의 제조 방법
CZ284168B6 (cs) Způsob navrhování a syntetizace antagonistů LHRH
WO2025232124A1 (en) Pharmaceutical compositions and their uses, and methods for improving the storage stability of pharmaceutical compositions
IE43770B1 (en) Calcitonin peptide preparations with prolonged action
US20040171531A1 (en) Non-aqueous injectable formulations for extended release of somatotropin
DE2306074A1 (de) Neue salze von acth-peptiden und verfahren zu ihrer herstellung
CH574247A5 (en) Oily, injectable peptide/aluminium alkanoate compsns - - with prolonged duration of activity
DE3915317A1 (de) Verwendung von gonadoliberinderivaten
SA01210722B1 (ar) تكوين صيدلي يحتوي على فولفسترانت fulvestrant